The main mechanism of action of Elotuzumab

The core mechanism of Elotuzumab (Elotuzumab) is based on targeting the SLAMF7 (also known as CS1) receptor, a protein highly expressed on the surface of multiple myeloma cells and natural killer cells (NK cells). By locking SLAMF7, evolizumab achieves directional recognition of malignant plasma cells and simultaneously activates the patient's own immune response. It is a representative drug with the dual mechanism of "targeted + immune enhancement" in modern immunotherapy.

Its working principle can be summarized into three key links. First, evolizumab can bind to SLAMF7 on the surface of tumor cells, making it easier for the immune system to recognize myeloma cells, which is equivalent to "marking" immune cells. Secondly, during the binding process, evolizumab activates NK cells and enhances their killing activity. NK cells are an important force in the human immune system responsible for clearing abnormal cells. Under the stimulation of evolizumab, their efficiency in identifying and destroying tumor cells is significantly improved. The third mechanism is through antibody-dependent cytotoxicity, that is, the combination of evolizumab with tumor cells triggers the immune pathway, allowing the cytotoxic reaction to act more concentratedly on the diseased site, reducing the impact on normal cells, and improving the selectivity of treatment.

This mechanism of "clear target, two-way regulation, and precise clearance" gives evolizumab more advantages in combination therapy. When paired with an immunomodulator, its activation effect is superimposed on the latter's ability to regulate T cells and NK cells, forming a synergistic anti-tumor model. Because its action does not rely on traditional chemotherapy mechanisms and does not overlap with cytotoxic drugs, it is of great significance for patients who have received multiple lines of treatment in the early stage.

Overall, the mechanism of action of evolizumab embodies the design concept of a new generation of immune-targeted therapy. Through the dual pathways of specific recognition and immune activation, it provides a more precise and sustainable treatment for multiple myeloma and other diseases.

Reference: https://www.empliciti.com/